Spots Global Cancer Trial Database for olverembatinib
Every month we try and update this database with for olverembatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia | NCT06401603 | Advanced Chroni... Philadelphia Ch... | Decitabine Listaftoclax Olverembatinib | 18 Years - | M.D. Anderson Cancer Center | |
| The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP | NCT06390306 | Chronic Myeloid... | Ponatinib Azacitidine Venetoclax Olverembatinib | 18 Years - | Peking University People's Hospital | |
| The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP | NCT06390306 | Chronic Myeloid... | Ponatinib Azacitidine Venetoclax Olverembatinib | 18 Years - | Peking University People's Hospital | |
| Olverembatinib for FGFR1-rearranged Neoplasms | NCT05521204 | Myeloproliferat... Acute Leukemia | Olverembatinib | - | The First Affiliated Hospital of Soochow University | |
| Olverembatinib for FGFR1-rearranged Neoplasms | NCT05521204 | Myeloproliferat... Acute Leukemia | Olverembatinib | - | The First Affiliated Hospital of Soochow University | |
| Olverembatinib for FGFR1-rearranged Neoplasms | NCT05521204 | Myeloproliferat... Acute Leukemia | Olverembatinib | - | The First Affiliated Hospital of Soochow University | |
| A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia | NCT06401603 | Advanced Chroni... Philadelphia Ch... | Decitabine Listaftoclax Olverembatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL | NCT05594784 | Philadelphia Ch... | Olverembatinib Venetoclax prednisone Vincristine | 14 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| A Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With CML | NCT06423911 | Chronic Myeloid... CML CML, Chronic Ph... | olverembatinib Bosutinib | 18 Years - 99 Years | Ascentage Pharma Group Inc. | |
| Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. | NCT05311943 | Olverembatinib Chronic Myeloid... Tyrosine Kinase... | olverembatinib | 18 Years - 75 Years | Shenzhen Second People's Hospital | |
| Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. | NCT05311943 | Olverembatinib Chronic Myeloid... Tyrosine Kinase... | olverembatinib | 18 Years - 75 Years | Shenzhen Second People's Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
